Advances in Contrast Media Research

Academic Radiology

Volumn 10, Issue 12, 2003, Pages 1450-1460

  Mattrey, Robert F ^a   Aguirre, Diego A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; CONTRAST MEDIUM; ECHO CONTRAST MEDIUM; GADOBENIC ACID; PENTETIC ACID;

COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG USE; EXTRACELLULAR FLUID; HUMAN; IMAGING; MAGNETIC RESONANCE ANGIOGRAPHY; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; SIDE EFFECT; ULTRASOUND;

EID: 0348014432     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1076-6332(03)00642-1     Document Type: Note

References (150)

1. Klibanov AL, Rasche PT, Hughes MS, et al. Detection of individual microbubbles of an ultrasound contrast agent: fundamental and pulse inversion imaging. Acad Radiol 2002; 9(Suppl 2):S279-281.
2. Ostensen J, Sontum PC, Hoff L, Bendiksen R. Microbubble volume concentration: a better efficacy parameter for US contrast agents than the number concentration. Acad Radiol 2002; 9(Suppl 1):S38-40.
3. Lei T, Udupa JK, Saha PK, et al. 3D MRA visualization and artery-vein separation using blood-pool contrast agent MS-325. Acad Radiol 2002; 9(Suppl 1):S127-133.
4. Brasch RC, Li KC, Husband JE, Keogan MT, Neeman M, Padhani AR, Shames D, Turetschek K. In vivo monitoring of tumor angiogenesis with MR imaging. Acad Radiol 2000; 7:812-823.
5. Mattrey RF, Long DM, Multer F, Mitten R, Higgins CB. Perfluorooctyl bromide: a reticuloendothelial-specific and a tumor imaging agent for computed tomography. Radiology 1982; 145:755-758.
6. Mattrey RF, André M, Campbell J, et al. Specific enhancement of intra-abdominal abscesses with perfluorooctyl bromide for CT imaging. Invest Radiol 1984; 19:438-446.
7. Mattrey RF. Perfluorooctyl bromide: a new contrast agent for CT, sonography, and MR imaging. Am J Roentgenol 1989; 152:247-252.
8. Brasch RC, Daldrup H, Shames D, Wendland M, Okuhata Y, Rosenau W. Macromolecular contrast media-enhanced MRI estimates of microvascular permeability correlate with histopathologic tumor grade. Acad Radiol 1998 Apr; 5(Suppl 1):S2-5.
9. Jiang Y, Zhao JJ, Tang H, et al. MRI of antigen-induced arthritis in rabbits: improved contrast and disease characterization with the blood pool agent MS-325. Acad Radiol 2002; 9(Suppl 2):S480.
10. Turetschek K, Preda A, Floyd E, et al. MRI monitoring of tumor response to a novel VEGF tyrosine kinase inhibitor in an experimental breast cancer model. Acad Radiol 2002; 9(Suppl 2):S519-520.
11. Helbich TH, Roberts TP, Rollins MD, et al. Noninvasive assessment of wound-healing angiogenesis with contrast-enhanced MRI. Acad Radiol 2002; 9(Suppl 1):S145-147.
12. Brasch RC, Gossmann A, Helbich TH, et al. Can a small-molecular gadolinium contrast agent be applied successfully with dynamic MRI to quantitatively define brain tumor microvascular responses to angiogenesis inhibition? Acad Radiol 2002; 9(Suppl 2):S326-327.
13. Clement O, Pradel C, Siauve N, et al. Assessing perfusion and capillary permeability changes induced by a VEGF inhibitor in human tumor xenografts using macromolecular MR imaging contrast media. Acad Radiol 2002; 9(Suppl 2):S328-329.
14. Daldrup-Link HE, Kaiser A, Link TM, et al. Comparison between gadopentetate and feruglose (Clariscan)-enhanced MR-mammography: preliminary clinical experience. Acad Radiol 2002; 9(Suppl 2):S343-347.
15. Turetschek K, Huber S, Helbich T, et al. Dynamic MRI enhanced with albumin-(Gd-DTPA)30 or ultrasmall superparamagnetic iron oxide particles (NC100150 injection) for the measurement of microvessel permeability in experimental breast tumors. Acad Radiol 2002; 9(Suppl 1):S112-114.
16. Roberts TP, Turetschek K, Preda A, et al. Tumor microvascular changes to anti-angiogenic treatment assessed by MR contrast media of different molecular weights. Acad Radiol 2002; 9(Suppl 2):S511-513.
17. Mattrey RF, Long DM, Peck WW, Slutsky RA, Higgins CB. Perfluorooctyl bromide as a blood pool contrast agent for liver, spleen, and vascular imaging in computed tomography. J Comput Assist Tomogr 1984; 8:739-744.
18. Behan M, O'Connell D, Mattrey RF, Carney DN. Perfluorooctyl bromide as a contrast agent for sonography and computed tomography. Am J Roentgenol 1993; 160:399-405.
19. Fouillet X, Tournier H, Khan H, et al. Enhancement of computed tomography liver contrast using iomeprol-containing liposomes and detection of small liver tumors in rats. Acad Radiol 1995 Jul; 2:576-583.
20. Vera DR, Mattrey RF. A molecular CT blood pool contrast agent. Acad Radiol 2002; 9:784-792.
21. Tournier H, Hyacinthe R, Schneider M. Gadolinium-containing mixed micelle formulations: a new class of blood pool MRI/MRA contrast agents. Acad Radiol 2002; 9(Suppl 1):S20-28.
22. Callot V, Canet E, Brochot J, et al. Hyperpolarized helium3 encapsulated in microbubbles: a new class of blood pool MRI contrast agent. Acad Radiol 2002; 9(Suppl 2):S501-503.
23. Robert P, Santus R, Violas X, Remy C, Corot C. Comparison of the tumoral biodistribution of P792, a rapid clearance blood pool agent and Gd-DOTA in a C6 glioma cerebral tumor model in rats. Acad Radiol 2002; 9(Suppl 2):S521-524.
24. Ruehm SG, Schmitz-Cristina H, Violas X, Corot C, Debatin JF. MR angiography with a new rapid clearance blood pool agent (P792): initial experience in rabbits. Acad Radiol 2002; 9(Suppl 2):S407-408.
25. Berthezene Y, Wiart M, Corot C, Violas X, Canet E. CT pulmonary angiography and perfusion: an experimental study using blood pool and nonspecific contrast agent. Acad Radiol 2002; 9(Suppl 2):S359-360.
26. Schnorr J, Wagner S, Pilgrimm H, Hamm B, Taupitz M. Preclinical characterization of monomer-stabilized very small superparamagnetic iron oxide particles (VSOP) as a blood pool contrast medium for MR angiography. Acad Radiol 2002; 9(Suppl 2):S307-309.
27. Tombach B, Reimer P, Mahler M, Ebert W, Pering C, Heindel W. First-pass and equilibrium phase MRA following intravenous bolus injection of SH U 555 C: phase I clinical trial in elderly volunteers with risk factors for arterial vascular disease. Acad Radiol 2002; 9(Suppl 2):S425-427.
28. Sahani D, Saini S, Sharma R, et al. Characterizing liver hemangiomas on ferumoxides-enhanced dynamic T1-weighted imaging: preliminary experience. Acad Radiol 2002; 9(Suppl 1):S255-256.
29. La Ferla R, Dapra M, Hentrich HR, Pirovano G, Kirchin MA. Gadobenate dimeglumine (Multihance) in contrast-enhanced magnetic resonance angiography. Acad Radiol 2002; 9(Suppl 2):S409-411.
30. Lohr HA, Froehlich JM, Pfyffer M, Bader CW, Zollikofer CL, Wentz KU. Comparison of Gd-BOPTA and Gd-DOTA for peripheral CE-MRA: a double-blind clinical study. Acad Radiol 2002; 9(Suppl 2):S421-424.
31. Mattrey RF. Potential role of perfluorooctyl bromide in the detection and characterization of liver lesions with CT. Radiology 1989; 170:18-20.
32. Gazelle GS, Wolf GL, McIntire GL, et al. Nanoparticulate computed tomography contrast agents for blood pool and liver-spleen imaging. Acad Radiol 1994; 1:373-376.
33. Mattrey RF, Kono Y, Mello M, Hassanein T, Hart M. Contribution of Feridex to liver MRI in end stage liver disease. 50th Annual Meeting American Association for the Study of Liver Diseases, Dallas. Hepatology 1999; 30:278A.
34. Akinci D, Oto A, Besim A, et al. Double contrast MR imaging of hepatocellular carcinoma evaluating lesion detection and conspicuity. Acad Radiol 2002; 9(Suppl 2):S466-467.
35. Helmberger T, Holzknecht N, Reiser M. Quantitative assessment of the contrast behavior of typical focal hepatic lesions before and after the administration of Gd-DTPA and superparamagnetic iron oxide particles. Acad Radiol 2002; 9(Suppl 2):S468-472.
36. Sahani DV, Saini S, Kalra MK, Michael M, Hahn PF. Liver lesion detection and characterization with sequential use of hepatobiliary contrast agent mangafodipir trisodium and gadolinium-DTPA in a single imaging protocol. Acad Radiol 2002; 9(Suppl 2):S460-462.
37. Koenig SH, Kellar KE, Fujii DK, Gunther WH, Briley-Saebo K, Spiller M. Three types of physical measurements needed to characterize iron oxide nanoparticles for MRI and MRA: magnetization, relaxometry, and light scattering. Acad Radiol 2002; 9(Suppl 1):S5-10.
38. Kellar KE, Fujii DK, Gunther WH, et al. Important considerations in the design of iron oxide nanoparticles as contrast agents for T1-weighted MRI and MRA. Acad Radiol 2002; 9(Suppl 1):S34-37.
39. Reimer P, Muller M, Marx C, Balzer T. Evaluation of the time window for Resovist-enhanced T2-weighted MRI of the liver. Acad Radiol 2002; 9(Suppl 2):S336-338.
40. Morana G, Grazioli L, Schneider G, et al. Hypervascular hepatic lesions: dynamic and late enhancement pattern with Gd-BOPTA. Acad Radiol 2002; 9(Suppl 2):S476-479.
41. Heussel CP, Mart-Bonmati L, L'Hermine C, et al. Gadodiamide and gadopentetate dimeglumine in MRI versus spiral CT in the diagnosis of liver lesions. Acad Radiol 2002; 9(Suppl 2):S463-465.
42. Hammerstingl R, Zangos S, Schwarz W, et al. Contrast-enhanced MRI of focal liver tumors using a hepatobiliary MR contrast agent: detection and differential diagnosis using Gd-EOB-DTPA-enhanced versus Gd-DTPA-enhanced MRI in the same patient. Acad Radiol 2002; 9(Suppl 1):S119-120.
43. Tanimoto A, Kadoya M, Kawamura Y, Kuwatsuru R, Gokan T, Hirohashi S. Safety and efficacy of a novel hepatobiliary MR contrast agent GN-1140 (Gd-DTPA-DeA): from the results of phase I and phase II clinical trials. Acad Radiol 2002; 9(Suppl 2):S457-459.
44. Pastor CM, Terrier F, Vallee JP. Hepatic kinetics of MRI contrast agents in the isolated perfused rat liver. Acad Radiol 2002; 9(Suppl 2):S455-456.
45. Vermess M, Doppman JL, Sugarbaker PH, et al. Computed tomography of the liver and spleen with intravenous lipoid contrast material: review of 60 examinations. Am J Roentgenol 1982; 138:1063-1071.
46. Rummeny EJ, Berning W, Fuest M, et al. New RES-specific contrast agents for CT. Acad Radiol 2002; 9(Suppl 1):S185-190.
47. Doerr-Stevens JK, Bakan DA, Lee FT Jr, et al. Imaging efficacy of a hepatocyte-selective polyiodinated triglyceride (DHOG-LE) for contrast-enhanced CT. Acad Radiol 2002; 9(Suppl 1):S200-204.
48. Bakan DA, Lee FT Jr, Weichert JP, Longino MA, Counsell RE. Hepatobiliary imaging using a novel hepatocyte-selective CT contrast agent. Acad Radiol 2002; 9(Suppl 1):S194-199.
49. Oussoren C, Zuidema J, Crommelin DJ, Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose. Biochim Biophys Acta 1997; 1328:261-272.
50. Ikomi F, Hanna GK, Schmid-Schonbein GW. Mechanism of colloidal particle uptake into the lymphatic system: basic study with percutaneous lymphography. Radiology 1995; 196:107-113.
51. Edge SB, Niland JC, Bookman MA, et al. Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers. J Natl Cancer Inst 2003; 95:1514-1521.
52. Vera DR, Wallace AM, Hoh CK, Mattrey RF. A synthetic macromolecule for sentinel node detection: (99m)Tc-DTPA-mannosyl-dextran. J Nucl Med 2001; 42:951-959.
53. Wallace AM, Hoh CK, Vera DR, Darrah DD, Schulteis G. Lymphoseek: a molecular radiopharmaceutical for sentinel node detection. Ann Surg Oncol 2003; 10:531-538.
54. Herborn CU, Lauenstein TC, Vogt FM, Lauffer RB, Debatin JF, Ruehm SG. Interstitial MR lymphography with MS-325: characterization of normal and tumor-invaded lymph nodes in a rabbit model. Am J Roentgenol 2002; 179:1567-1572.
55. Herborn CU, Vogt FM, Lauenstein TC, et al. Assessment of normal, inflammatory, and tumor-bearing lymph nodes with contrast-enhanced interstitial magnetic resonance lymphography: preliminary results in rabbits. J Magn Reson Imaging 2003; 18:328-335.
56. Kobayashi H, Kawamoto S, Star RA, Waldmann TA, Tagaya Y, Brechbiel MW. Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent. Cancer Res 2003; 63:271-276.
57. Harisinghani MG, Barentsz JO, Hahn PF, et al. MR lymphangiography for detection of minimal nodal disease in patients with prostate cancer. Acad Radiol 2002; 9(Suppl 2):S312-313.
58. Michel SC, Keller TM, Frohlich JM, et al. Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement. Radiology 2002; 225:527-536.
59. Anzai Y, Piccoli CW, Outwater EK, et al. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. Radiology 2003; 228:777-788.
60. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348:2491-2499.
61. Ruehm SG, Corot C, Vogt P, Cristina H, Debatin JF. Ultrasmall superparamagnetic iron oxide-enhanced MR imaging of atherosclerotic plaque in hyperlipidemic rabbits. Acad Radiol 2002; 9(Suppl 1):S143-144.
62. Schmitz SA, Winterhalter S, Schiffler S, et al. USPIO-enhanced direct thrombus MRI. Acad Radiol 2002; 9(Suppl 2):S339-340.
63. Wolf GL, Rogowska J, Hanna GK, Halpern EF. Percutaneous CT lymphography with perflubron: imaging efficacy in rabbits and monkeys. Radiology 1994; 191:501-505.
64. Hanna G, Hopkins R, Flaim K, Leese P, Schmid-Schonbein G, Wolf GL. Indirect lymphography with perflubron emulsion. Preclinical and clinical results. Invest Radiol 1994; 29(Suppl 2):S33-35.
65. Wolf GL, Gazelle GS, McIntire GL, et al. Percutaneous computed tomography lymphography in the rabbit by subcutaneously injected nanoparticulates. Acad Radiol 1994; 1:352-3571.
66. Desser TS, Rubin DL, Muller H, McIntire GL, Bacon ER, Hollister KR. Interstitial MR and CT lymphography with Gd-dTPA-co-alpha, omega-diaminoPEG(1450) and Gd-dTPA-co-1,6-diaminohexane polymers: preliminary experience. Acad Radiol 1999; 6:112-118.
67. Suga K, Ogasawara N, Okada M, Matsunaga N. Interstitial CT lymphography-guided localization of breast sentinel lymph node: preliminary results. Surgery 2003; 133:170-179.
68. Wisner ER, Theon AP, Katzberg RW, Griffey SM, McIntire GL. Lymph node uptake of interstitially delivered particulate contrast media before and after irradiation in dogs. Acad Radiol 1999; 6:119-125.
69. Wisner ER, Weichert JP, Longino MA, Counsell RE, Weisbrode SE. Percutaneous CT lymphography using a new polyiodinated biomimetic microemulsion. Acad Radiol 2002; 9(Suppl 1):S191-193.
70. Wrigley RW, Saunders HB, Lim G, Arellano RA, Mattrey RF. Indirect ultrasonographic lymphography with perflubron emulsion. Radiology 1993; 189(P):285.
71. Schutt EG, Pelura TJ, Hopkins RM. Osmotically stabilized microbubble sonographic contrast agents. Acad Radiol 1996; 2(Suppl 3):S188-190.
72. Mattrey RF, Kono Y, Baker K, Peterson T. Sentinel lymph node imaging with microbubble ultrasound contrast material. Acad Radiol 2002; 9(Suppl 1):S231-235.
73. Wisner ER, Ferrara K, Gabe JD, et al. Contrast enhanced intermittent power Doppler ultrasound with sub-micron bubbles for sentinel node detection. Acad Radiol 2002; 9(Suppl 2):S389-391.
74. Tornes A, Forsberg F, Goldberg B, Hvoslef AM, Ostensen J, Rasmussen H. Sentinel lymph node identification with an ultrasound contrast agent: An experimental study in pigs. Radiology 2002; 225(Suppl):586.
75. Trends in Contrast Media. Thomsen HS, Muller R, Mattrey RF, eds. Medical Radiology-Diagnostic Imaging and Radiation Oncology series. Berlin: Springer-Verlag, 1999
76. Mattrey RF, Scheible FW, Gosink BB, Leopold GR, Long DM, Higgins CB. Perfluorooctyl bromide: a liver/spleen-specific and a tumor-imaging ultrasound contrast material. Radiology 1982; 145:759-762.
77. Mattrey RF, Strich G, Shelton RE, et al. Perfluorochemicals as US contrast agents for tumor imaging and hepatosplenography: preliminary clinical results. Radiology 1987; 163:339-343.
78. Mattrey RF, Wrigley R, Steinbach GC, Schutt EG, Evitts DP. Gas emulsions as ultrasound contrast agents. Preliminary results in rabbits and dogs. Invest Radiol 1994; 29(Suppl 2):S139-141.
79. Schutt EG, Klein DH, Mattrey RM, Riess JG. Injectable microbubbles as contrast agents for diagnostic ultrasound imaging: the key role of perfluorochemicals. Angew Chem Int Ed Engl 2003; 42:3218-235.
80. Albrecht T, Hoffmann CW, Schettler S, et al. Improved detection of liver metastases with phase inversion ultrasound during the late phase of levovist. Acad Radiol 2002; 9(Suppl 1):S236-239.
81. Albrecht T, Overberg A, Hoffmann CW, et al. Characterization of focal liver lesions with phase inversion ultrasound during the late liver-specific phase of Levovist. Acad Radiol 2002; 9(Suppl 2):S375.
82. Basilico R, Blomley MJ, Cosgrove DO, et al. The first phase I study of a novel ultrasound contrast agent (BR14): assessment of safety and efficacy in liver and kidneys. Acad Radiol 2002; 9(Suppl 2):S380-381.
83. Bauer A, Becher H, Blomley M, et al. Ultrasonic imaging of organ perfusion with SH U 563A. Acad Radiol 2002; 9(Suppl 1):S46-51.
84. Moriyasu F, Migihashi R, Matsumura T, Toda Y, Chiba T. Harmonic gray scale 3D contrast imaging of the liver. Acad Radiol 2002; 9(Suppl 1):S228-230.
85. Rosenberg ML, Carpenter AP. Contrast material-enhanced abdominal US examinations with DMP 115 (DEFINITY) provides additional diagnostic information with potential for changes in patient management. Acad Radiol 2002; 9(Suppl 1):S243-245.
86. Spinazzi A, Llull JB. Diagnostic performance of SonoVue-enhanced color duplex sonography of vascular structures. Acad Radiol 2002; 9(Suppl 1):S246-250.
87. Esteban JM, Gil J. Therapeutic effect of chemoembolization therapy on hepatocellular carcinoma: evaluation with contrast-enhanced power Doppler sonography and contrast-enhanced harmonic imaging. Acad Radiol 2002; 9(Suppl 2):S382-383.
88. Holscher T, Postert T, Meves S, et al. Assessment of brain perfusion with echo contrast specific imaging modes and Optison. Acad Radiol 2002; 9(Suppl 2):S386-388.
89. Krestan CR, Riedl C, Memarsadeghi M, Rudas M, Pfarl G, Helbich TH. 3D-power Doppler ultrasound of breast lesions with a microbubble contrast agent. Acad Radiol 2002; 9(Suppl 2):S384-385.
90. Lencioni R, Cioni D, Crocetti L, et al. Ultrasound imaging of focal liver lesions with a second-generation contrast agent. Acad Radiol 2002; 9(Suppl 2):S371-374.
91. Bauer A, Solbiati L, Weissman N. Ultrasound imaging with SonoVue: low mechanical index real-time imaging. Acad Radiol 2002; 9(Suppl 2):S282-284.
92. Ostensen J, Bendiksen R. Characterization and use of ultrasound contrast agents. Acad Radiol 2002; 9(Suppl 2):S276-278.
93. Quaia E, Stacul F, Bertolotto M, Locatelli M, Mucelli RP. Characterization of focal liver lesions with pulse inversion harmonic imaging (PIHI) using a second generation US contrast agent. Acad Radiol 2002; 9(Suppl 2):S376-379.
94. Correas JM, Lai X, Qi X, Burns PN, Moreau JF. In vivo quantification of a US contrast agent: pulsed Doppler intensitometry vs power Doppler quantification. Acad Radiol 2002; 9(Suppl 1):S227.
95. Eyding J, Wilkening W, Reckhardt M, et al. Contrast burst depletion imaging (CODIM): a new imaging procedure and analysis method for semiquantitative ultrasonic perfusion imaging. Stroke 2003; 34:77-83.
96. Schlief R, Alhassan A, Wiggins J, Schumann W, Niendorf HP. Safety of the galactose-based ultrasound contrast agent levovist. Acad Radiol 2002; 9(Suppl 1):S240-242.
97. Klibanov AL, Hughes MS, Wojdyla JK, Wible JH Jr, Brandenburger GH. Destruction of contrast agent microbubbles in the ultrasound field: the fate of the microbubble shell and the importance of the bubble gas content. Acad Radiol 2002; 9(Suppl 1):S41-45.
98. Satterfield R, Tarter M, Schumacher D, Tran P, Mattrey RF. Comparison of different perfluorocarbons as ultrasound contrast agents. Invest Radiol 1993; 28:325-331.
99. Lanza GM, Wallace KD, Scott MJ, et al. A novel site-targeted ultrasonic contrast agent with broad biomedical application [published erratum appears in Circulation 1997; 95:2458]. Circulation 1996; 94:3334-3340.
100. Lanza GM, Wallace KD, Scott MJ, et al. A novel site-targeted ultrasonic contrast agent with broad biomedical application [published erratum appears in Circulation 1997; 95:2458]. Circulation 1996; 94:3334-3340.
101. Bremer C, Tung CH, Bogdanov A Jr, Weissleder R. Imaging of differential protease expression in breast cancers for detection of aggressive tumor phenotypes. Radiology 2002; 222:814-818.
102. Louie AY, Huber MM, Ahrens ET, et al. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 2000; 18:321-325.
103. Lanza GM, Abendschein DR, Hall CS, et al. In vivo molecular imaging of stretch-induced tissue factor in carotid arteries with ligand-targeted nanoparticles. J Am Soc Echocardiogr 2000; 13:608-614.
104. Lanza GM, Abendschein DR, Yu X, et al. Molecular imaging and targeted drug delivery with a novel, ligand-directed paramagnetic nanoparticle technology. Acad Radiol 2002; 9(Suppl 2):S330-331.
105. Unger EC, Matsunaga TO, McCreery TP, Sweitzer RH. Biomedical implications of a thrombus-specific US contrast agent. Acad Radiol 2002; 9(Suppl 1):S56-57.
106. Tardy I, Pochon S, Theraulaz M, Nanjappan P, Schneider M. In vivo ultrasound imaging of thrombi using a target-specific contrast agent. Acad Radiol 2002; 9(Suppl 2):S294-296.
107. Lindner JR. Evolving applications for contrast ultrasound. Am J Cardiol 2002; 90:72J-80J.
108. Leong-Poi H, Christiansen J, Klibanov AL, Kaul S, Lindner JR. Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to alpha(v)-integrins. Circulation 2003; 107:455-460.
109. Ellegala DB, Leong-Poi H, Carpenter JE, et al. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation 2003; 108:336-341. Epub 2003 Jun 30.
110. Weller GE, Villanueva FS, Klibanov AL, Wagner WR. Modulating targeted adhesion of an ultrasound contrast agent to dysfunctional endothelium. Ann Biomed Eng 2002; 30:1012-1019.
111. Weller GE, Lu E, Csikari MM, et al. Ultrasound imaging of acute cardiac transplant rejection with microbubbles targeted to intercellular adhesion molecule-1. Circulation 2003; 108:218-224.
112. Bulte JW, Zhang SC, van Gelderen P, et al. Magnetically labeled glial cells as cellular MR contrast agents. Acad Radiol 2002; 9(Suppl 1):S148-150.
113. Bulte JW, Douglas T, Witwer B, et al. Monitoring stem cell therapy in vivo using magnetodendrimers as a new class of cellular MR contrast agents. Acad Radiol 2002; 9(Suppl 2):S332-335.
114. Frank JA, Zywicke H, Jordan EK, et al. Magnetic intracellular labeling of mammalian cells by combining (FDA-approved) superparamagnetic iron oxide MR contrast agents and commonly used transfection agents. Acad Radiol 2002; 9(Suppl 2):S484-487.
115. Schellenberger EA, Hogemann D, Josephson L, Weissleder R. Annexin V-CLIO: a nanoparticle for detecting apoptosis by MRI. Acad Radiol 2002; 9(Suppl 2):S310-311.
116. Wiener EC, Konda SD, Wang S, Brechbiel M. Imaging folate binding protein expression with MRI. Acad Radiol 2002; 9(Suppl 2):S316-319.
117. Wunderbaldinger P, Josephson L, Weissleder R. Crosslinked iron oxides (CLIO): a new platform for the development of targeted MR contrast agents. Acad Radiol 2002; 9(Suppl 2):S304-306.
118. Licha K, Riefke B, Ebert B, Grotzinger C. Cyanine dyes as contrast agents in biomedical optical imaging. Acad Radiol 2002; 9(Suppl 2):S320-322.
119. Fujimoto JG, Bouma B, Tearney GJ, et al. New technology for high-speed and high-resolution optical coherence tomography. Ann N Y Acad Sci 1998; 838:95-107.
120. Bouma BE, Tearney GJ. Clinical imaging with optical coherence tomography. Acad Radiol 2002; 9:942-953.
121. Barton JK, Hoying JB, Sullivan CJ. Use of microbubbles as an optical coherence tomography contrast agent. Acad Radiol 2002; 9(Suppl 1):S52-55.
122. Tromberg BJ, Shah N, Lanning R, et al. Non-invasive in vivo characterization of breast tumors using photon migration spectroscopy. Neoplasia 2000; 2:26-40.
123. Ntziachristos V, Chance B. Probing physiology and molecular function using optical imaging: applications to breast cancer. Breast Cancer Res 2001; 3:41-46. Epub 2000 Nov 29.
124. Chance B. Near-infrared (NIR) optical spectroscopy characterizes breast tissue hormonal and age status. Acad Radiol 2001; 8:209-210.
125. McCaffrey A, Kay MA, Contag CH. Advancing molecular therapies through in vivo bioluminescent imaging. Mol Imaging 2003; 2:75-86.
126. Bremer C, Weissleder R. In vivo imaging of gene expression. Acad Radiol 2001; 8:15-23.
127. Bremer C, Tung CH, Weissleder R. Molecular imaging of MMP expression and therapeutic MMP inhibition. Acad Radiol 2002; 9(Suppl 2):S314-15.
128. Ntziachristos V, Bremer C, Tung C, Weissleder R. Imaging cathepsin B up-regulation in HT-1080 tumor models using fluorescence-mediated molecular tomography (FMT). Acad Radiol 2002; 9(Suppl 2):S323-325.
129. Albert MS, Balamore D. Development of hyperpolarized noble gas MRI. Nucl Instrum Methods Phys Res A 1998; 402:441-453.
130. Kauczor H, Surkau R, Roberts T. MRI using hyperpolarized noble gases. Eur Radiol 1998; 8:820-827.
131. Duhamel G, Choquet P, Grillon E, et al. Global and regional cerebral blood flow measurements using NMR of injected hyperpolarized xenon-129. Acad Radiol 2002; 9(Suppl 2):S498-500.
132. Kauczor HU, Hyperpolarized 3helium gas as a novel contrast agent for functional MRI of ventilation. Acad Radiol 2002; 9(Suppl 2):S504-506.
133. Venkatesh AK, Zhao L, Balamore D, Jolesz FA, Albert MS. Hyperpolarized 129Xe MRI using gas-filled liposomes. Acad Radiol 2002; 9(Suppl 1):S270-274.
134. Golman K, Ardenkjaer-Larsen JH, Svensson J, et al. 13C-angiography. Acad Radiol 2002; 9(Suppl 2):S507-510.
135. Rizi RR, Lipson DA, Dimitrov IE, Ishii M, Roberts DA. Operating characteristics of hyperpolarized 3He and arterial spin tagging in MR imaging of ventilation and perfusion in healthy subjects. Acad Radiol 2003; 10:502-508.
136. Mishkin MM. Contrast media safety: what do we know and how do we know it? Am J Cardiol 1990; 66:34F-36F.
137. Lasser EC. Pretreatment with corticosteroids to prevent reactions to i. v. contrast material: overview and implications. Am J Roentgenol 1988; 150:257-259.
138. Munechika H, Hiramatsu Y, Kudo S, et al. Delayed adverse reactions to nonionic contrast medium (iohexol) in IV use: multicentric study. Acad Radiol 2002; 9(Suppl 1):S69-71.
139. Harz C, Fallenberg EM, Schafer R, et al. Two-center clinical study on the effect of chronic renal impairment on safety of iopromide 300 mg iodine/mL. Acad Radiol 2002; 9(Suppl 2):S535-539.
140. Laroche D, Vergnaud MC, Lefrancois C, Hue S, Bricard H. Anaphylactoid reactions to iodinated contrast media. Acad Radiol 2002; 9(Suppl 2):S431-432.
141. Lasser EC, Lamkin GE. Mechanisms of blood pressure change after bolus injections of X-ray contrast media. Acad Radiol 2002; 9(Suppl 1):S72-75.
142. Elmstahl B, Leander P, Nyman U, Chai CM, Almen T, Frennby B. Nephrotoxicity after renal angiography using iodine and gadolinium contrast media in pigs with renal damage. Acad Radiol 2002; 9(Suppl 2):S531-534.
143. Sandhu C, Newman DJ, Morgan R, Belli AM, Oliveira D. The role of oxygen free radicals in contrast induced nephrotoxicity. Acad Radiol 2002; 9(Suppl 2):S436-437.
144. Wiggins J, Beckmann R, Weinmann HJ, Lehr R. Electrocardiographic effects of diagnostic imaging agents. Acad Radiol 2002; 9(Suppl 2):S444-446.
145. Pettersson G, Towart R, Grant D, Thyberg K, Golman K. The rabbit renal toxicity test: a sensitive in vivo test for the nephrotoxicity of contrast agents. Acad Radiol 2002; 9(Suppl 1)S62-64.
146. Thomsen HS, Morcos SK. Prevention of generalized reactions to CM. Acad Radiol 2002; 9(Suppl 2):S433-435.
147. Cochran ST, Bomyea K. Trends in adverse events from iodinated contrast media. Acad Radiol 2002; 9(Suppl 1):S65-68.
148. Siegle RL. Contrast agent reactions and free will. Acad Radiol 2002; 9(Suppl 1):S76-77.
149. Almen T, Chai CM, Besjakov J, Baath L. Adding sodium and calcium ions to iodixanol and mannitol: effects on risk of ventricular fibrillation after infusion into the left coronary artery of pigs. Acad Radiol 2002; 9(Suppl 2):S441-443.
150. Cochran ST, Bomyea K, Kahn M. Treatment of iodinated contrast material extravasation with hyaluronidase. Acad Radiol 2002; 9(Suppl 2):S544-546.